Get To Know Us

Peter G. Kleinhenz

Peter G. Kleinhenz

Co-founder & Board Chair

Peter Kleinhenz is an accomplished life sciences leader and successful venture capitalist. Mr. Kleinhenz most recently served as the CFO and CBO at Myonexus Therapeutics, Inc, a clinical stage gene-therapy company pioneering in limb girdle muscular dystrophy treatments, which was acquired by Sarepta Therapeutics in April 2019. Previously, Mr. Kleinhenz was Partner and Managing Director at Fletcher Spaght Ventures and CID Capital, Inc. and served in numerous board and advisory roles for growing life science companies. Peter’s leadership experience spans business development, financial strategy and executive leadership at companies including Battelle Memorial Institute; Progenics Inc., and Neoprobe Corporation. He co-founded the MidAmerica Health Innovation Network and has served as a board member of BioOhio for over 20 years. Peter received a bachelor’s degree from Loyola University of Chicago, and his MBA from Case Western Reserve University.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.